Oxylipins in triglyceride-rich lipoproteins of dyslipidemic subjects promote endothelial inflammation following a high fat meal.
Adult
Aged
Case-Control Studies
Cell Line
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Dietary Fats
/ administration & dosage
Dyslipidemias
/ blood
Endothelial Cells
/ cytology
Epoxide Hydrolases
/ genetics
Fasting
Fatty Acids, Unsaturated
/ administration & dosage
Female
Gene Expression Regulation
/ drug effects
Humans
Inflammation
Lipoproteins
/ blood
Lipoxygenase
/ genetics
Male
Meals
Middle Aged
Oxylipins
/ administration & dosage
Postprandial Period
Triglycerides
/ blood
Tumor Necrosis Factor-alpha
/ pharmacology
Vascular Cell Adhesion Molecule-1
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 06 2019
17 06 2019
Historique:
received:
18
12
2018
accepted:
28
05
2019
entrez:
19
6
2019
pubmed:
19
6
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Elevated triglyceride-rich lipoproteins (TGRL) in circulation is a risk factor for atherosclerosis. TGRL from subjects consuming a high saturated fat test meal elicited a variable inflammatory response in TNFα-stimulated endothelial cells (EC) that correlated strongly with the polyunsaturated fatty acid (PUFA) content. This study investigates how the relative abundance of oxygenated metabolites of PUFA, oxylipins, is altered in TGRL postprandially, and how these changes promote endothelial inflammation. Human aortic EC were stimulated with TNFα and treated with TGRL, isolated from subjects' plasma at fasting and 3.5 hrs postprandial to a test meal high in saturated fat. Endothelial VCAM-1 surface expression stimulated by TNFα provided a readout for atherogenic inflammation. Concentrations of esterified and non-esterified fatty acids and oxylipins in TGRL were quantified by mass spectrometry. Dyslipidemic subjects produced TGRL that increased endothelial VCAM-1 expression by ≥35%, and exhibited impaired fasting lipogenesis activity and a shift in soluble epoxide hydrolase and lipoxygenase activity. Pro-atherogenic TGRL were enriched in eicosapentaenoic acid metabolites and depleted in esterified C18-PUFA-derived diols. Abundance of these metabolites was strongly predictive of VCAM-1 expression. We conclude the altered metabolism in dyslipidemic subjects produces TGRL with a unique oxylipin signature that promotes a pro-atherogenic endothelial phenotype.
Identifiants
pubmed: 31209255
doi: 10.1038/s41598-019-45005-5
pii: 10.1038/s41598-019-45005-5
pmc: PMC6572825
doi:
Substances chimiques
Cholesterol, HDL
0
Cholesterol, LDL
0
Dietary Fats
0
Fatty Acids, Unsaturated
0
Lipoproteins
0
Oxylipins
0
Triglycerides
0
Tumor Necrosis Factor-alpha
0
Vascular Cell Adhesion Molecule-1
0
lipoprotein triglyceride
0
Lipoxygenase
EC 1.13.11.12
Epoxide Hydrolases
EC 3.3.2.-
EPHX2 protein, human
EC 3.3.2.10
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
8655Subventions
Organisme : NIAID NIH HHS
ID : R01 AI047294
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL082689
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK097154
Pays : United States
Références
Front Genet. 2014 May 09;5:112
pubmed: 24847353
Circulation. 2005 Nov 15;112(20):3066-72
pubmed: 16275870
J Clin Invest. 1993 Mar;91(3):748-58
pubmed: 8450056
Adv Nutr. 2015 Sep 15;6(5):513-40
pubmed: 26374175
Biochem Pharmacol. 2010 Mar 15;79(6):880-7
pubmed: 19896470
J Intern Med. 1999 Oct;246(4):341-55
pubmed: 10583705
Arterioscler Thromb Vasc Biol. 1999 Nov;19(11):2615-22
pubmed: 10559003
Circ Res. 2007 Feb 16;100(3):381-90
pubmed: 17234968
JAMA. 2005 Jul 20;294(3):326-33
pubmed: 16030277
Curr Atheroscler Rep. 2009 Nov;11(6):403-10
pubmed: 19852880
Circulation. 2002 Mar 5;105(9):1135-43
pubmed: 11877368
Biochem Biophys Res Commun. 2013 Apr 26;434(1):173-8
pubmed: 23537656
J Lipid Res. 2017 Jan;58(1):188-195
pubmed: 27875258
Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1260-6
pubmed: 16543492
J Mol Med (Berl). 2009 Apr;87(4):379-84
pubmed: 19259639
Circ Res. 2012 Sep 28;111(8):1054-64
pubmed: 22874466
PLoS One. 2012;7(11):e48852
pubmed: 23144998
Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H784-91
pubmed: 21169396
Eur Heart J. 2011 Jun;32(11):1345-61
pubmed: 21531743
Exp Ther Med. 2015 Aug;10(2):423-428
pubmed: 26622332
Front Physiol. 2017 Nov 08;8:902
pubmed: 29167646
Nutr Metab Cardiovasc Dis. 2008 Jul;18(6):436-40
pubmed: 18068341
Prostaglandins Leukot Essent Fatty Acids. 2018 Jan;128:1-10
pubmed: 29413356
Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):e19-24
pubmed: 14766740
Circ Res. 2016 Feb 19;118(4):547-63
pubmed: 26892957
Mol Nutr Food Res. 2014 Mar;58(3):591-600
pubmed: 24127338
J Biol Chem. 2013 May 17;288(20):14189-99
pubmed: 23576437
Am J Clin Nutr. 2008 Jul;88(1):203-9
pubmed: 18614742
Atherosclerosis. 2000 May;150(1):167-77
pubmed: 10781648
Dis Model Mech. 2009 May-Jun;2(5-6):231-7
pubmed: 19407331
Curr Atheroscler Rep. 2010 May;12(3):174-83
pubmed: 20425256
J Clin Exp Cardiolog. 2014;5:
pubmed: 25598995
Circulation. 2011 May 24;123(20):2292-333
pubmed: 21502576
J Cardiovasc Pharmacol. 2008 Oct;52(4):314-23
pubmed: 18791465
Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9772-7
pubmed: 15994227
J Clin Biochem Nutr. 2011 Sep;49(2):131-5
pubmed: 21980230
Toxicol Appl Pharmacol. 2015 Jul 15;286(2):102-11
pubmed: 25827057
Anal Bioanal Chem. 2016 Jan;408(1):97-105
pubmed: 26511226
J Mol Cell Cardiol. 2016 May;94:180-188
pubmed: 27079253
J Clin Invest. 2001 May;107(10):1255-62
pubmed: 11375415
Sci Rep. 2016 Jun 27;6:28418
pubmed: 27344992
PLoS One. 2013 Oct 21;8(10):e78322
pubmed: 24205197
Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):193-7
pubmed: 15499043
Int J Clin Pract. 2010 Feb;64(3):389-403
pubmed: 20456177
Circ Res. 2016 Feb 19;118(4):620-36
pubmed: 26892962
Am J Physiol Endocrinol Metab. 2012 Mar 15;302(6):E654-65
pubmed: 22215650
Prostaglandins Leukot Essent Fatty Acids. 2008 Dec;79(6):215-22
pubmed: 19042114